Advances in Treating PNH (Paroxysmal Nocturnal Hemoglobinuria) with Dr. Allyson Pishko - 2022
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Transplant for Older Patients with Dr. Nandita Khera - 2022
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Treatment Options for MDS (Myelodysplastic Syndromes) with Dr. Rory Shallis - 2022
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Treating MDS after Hypomenthylating Failure with Dr. Jacqueline Garcia - 2022
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Key Points
Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD.
Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids.
Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
Patients With MPNs Must Be Honest About Their Symptoms, Says Expert
It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.
Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team.
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated
The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator
PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”